NCT01716351

Brief Summary

Psychosocial risks are significant in the management of patients with cardiovascular disease and implantable cardioverter defibrillators (ICD) devices. This is a randomized, controlled, clinical study. The hypothesis is that adapted yoga (vs. usual care) will significantly reduce psychosocial risks (e.g. anxiety and depression symptoms) and improve the quality of life in ICD patients. The specialized, real-time data, collected by the device provides a unique look at the electrophysiological parameters of each patient's heart.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
55

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2007

Longer than P75 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2007

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2010

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2011

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

October 17, 2012

Completed
12 days until next milestone

First Posted

Study publicly available on registry

October 29, 2012

Completed
Last Updated

October 29, 2012

Status Verified

October 1, 2012

Enrollment Period

3.3 years

First QC Date

October 17, 2012

Last Update Submit

October 24, 2012

Conditions

Keywords

Randomized Clinical Control TrialComplementary and Alternative MedicineYogaElectrophysiologyImplantable Cardioverter DefibrillatorPsychosocialAnxietySelf-CompassionAnti-Tachycardia Pacing Events

Outcome Measures

Primary Outcomes (9)

  • Florida Shock Anxiety Scale (FSAS)

    A 10-item list which measures patient fears about implantable cardioverter defibrillator shock.

    Baseline

  • Florida Shock Anxiety Scale (FSAS)

    A 10-item list which measures patient fears about implantable cardioverter defibrillator shock.

    End of Intervention (8 weeks)

  • Self-Compassion Scale

    A 26-item self-report scale that measures self-kindness, self-judgement, common humanity, isolation, mindfulness and over-identification.

    Baseline

  • Self-Compassion Scale

    A 26-item self-report scale that measures self-kindness, self-judgement, common humanity, isolation, mindfulness and over-identification.

    End of Intervention (8 weeks)

  • The number of device-initiated ventricular defibrillations as recorded by their ICD device

    A record of device firings from the Implantable Cardioverter Defibrillator (ICD) device data.

    Baseline

  • The number of device-initiated ventricular defibrillations as recorded by their ICD device

    A record of device firings from the Implantable Cardioverter Defibrillator (ICD) device data.

    Six month follow-up

  • The number of anti-tachycardia pacing events among participants as recorded by their ICD device

    As measured by each ICD device, the number of times that the device therapeutically paced the heart faster than its intrinsic rate, known as anti-tachycardia pacing (ATP), was recorded for each participant.

    Baseline

  • The number of anti-tachycardia pacing events among participants as recorded by their ICD device

    As measured by each ICD device, the number of times that the device therapeutically paced the heart faster than its intrinsic rate, known as anti-tachycardia pacing (ATP), was recorded for each participant.

    End of Intervention (8 weeks)

  • The number of anti-tachycardia pacing events among participants as recorded by their ICD device

    As measured by each ICD device, the number of times that the device therapeutically paced the heart faster than its intrinsic rate, known as anti-tachycardia pacing (ATP), was recorded for each participant.

    Six month follow-up

Secondary Outcomes (30)

  • Expression Manipulation Test

    Baseline

  • Expression Manipulation Test

    End of Intervention (8 weeks)

  • Pennebaker Inventory

    Baseline

  • Pennebaker Inventory

    End of Intervention (8 weeks)

  • State-Trait Anxiety Inventory (STAI)

    Baseline

  • +25 more secondary outcomes

Study Arms (2)

Adapted Yoga Intervention Group

EXPERIMENTAL

Patients received the Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients and a call from a cardiac research nurse once monthly for five months.

Behavioral: Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients

Control

NO INTERVENTION

Patients received usual care and a call from a cardiac research nurse once monthly for five months to control for attention.

Interventions

A weekly 80-minute standardized, repeatable adapted Yoga program designed for recipients of Implantable Cardioverter Defibrillators, including a 30-minute home practice CD.

Adapted Yoga Intervention Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Receipt of Implantable Cardioverter Defibrillator for 6 weeks or more
  • Must be 18 or more years of age

You may not qualify if:

  • Patients requiring more than 48 hours of hospitalization for implantation
  • Mental Incompetence (Dementia)
  • Physician's contra-indication

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Arrhythmias, CardiacAnxiety Disorders

Interventions

Defibrillators, Implantable

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsMental Disorders

Intervention Hierarchy (Ancestors)

DefibrillatorsElectrodesElectrical Equipment and SuppliesEquipment and SuppliesElectrodes, ImplantedProstheses and Implants

Study Officials

  • Stefanie CF Toise, PhD, MPH

    Yale New Haven Hospital, St. Raphael Campus

    PRINCIPAL INVESTIGATOR
  • Thomas J Donohue, MD

    Yale New Haven Hospital, St. Raphael Campus

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 17, 2012

First Posted

October 29, 2012

Study Start

August 1, 2007

Primary Completion

November 1, 2010

Study Completion

February 1, 2011

Last Updated

October 29, 2012

Record last verified: 2012-10